Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

杜瓦卢马布 银耳霉素 吉西他滨 医学 内科学 顺铂 化疗 肿瘤科
作者
Do-Youn Oh,Kyung-Hun Lee,Dae-Won Lee,Jeesun Yoon,Tae-Yong Kim,Ju-Hee Bang,Ah-Rong Nam,Kyoung-Seok Oh,Jae-Min Kim,Young Lee,Violeta Guthrie,Patricia McCoon,Weimin Li,Song Wu,Qu Zhang,Marlon C Rebelatto,Jin Won Kim
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (6): 522-532
标识
DOI:10.1016/s2468-1253(22)00043-7
摘要

Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.This open-label, single-centre, phase 2 study was conducted at Seoul National University Hospital. Eligible patients were treatment-naïve adults aged 18 years or older with histologically proven unresectable or recurrent biliary tract cancer, at least one measurable lesion based on the Response Evaluation Criteria in Solid Tumors (version 1.1), an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 12 weeks or longer, and adequate healthy organ and bone marrow function. Initially, all patients received one 3-week cycle of gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) on day 1 and 8 followed by gemcitabine and cisplatin plus durvalumab (1120 mg) and tremelimumab (75 mg) on day 1 of each cycle, starting with the second cycle (chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group). Following protocol amendment, patients were recruited to receive gemcitabine and cisplatin plus durvalumab, starting on day 1 of the first cycle (chemotherapy plus durvalumab group) or gemcitabine and cisplatin plus durvalumab and tremelimumab also from day 1 of the first cycle (chemotherapy plus durvalumab and tremelimumab group) in parallel and allocated using a random block method. Assessors and patients were not masked to the treatment group. The primary endpoint was objective response rate, assessed in the efficacy population (ie, patients who were treated at least until the first tumour response assessment). This study is registered with ClinicalTrials.gov, NCT03046862 (active).Between March 2, 2017, and Feb 13, 2020, 128 patients were enrolled (32 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 49 in the chemotherapy plus durvalumab group, and 47 in the chemotherapy plus durvalumab and tremelimumab group). Four patients (two in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group and two in the chemotherapy plus durvalumab group) were excluded and 124 were evaluable for tumour response. The median duration of follow-up was 48·2 months (IQR 41·5-49·4) for the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 26·6 months (19·0-27·9) for the chemotherapy plus durvalumab group, and 24·2 months (20·7-31·7) for the chemotherapy plus durvalumab and tremelimumab group. 82 (66%) of 124 patients achieved an objective response (15 [50%] of 30 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 34 [72%] of 47 in the chemotherapy plus durvalumab group, and 33 [70%] of 47 in the chemotherapy plus durvalumab and tremelimumab group). The most common grade 3 and 4 adverse events were decreased neutrophil count (67 [53%] of 126), anaemia (50 [40%]), and decreased platelet count (24 [19%]), with no unexpected safety events. No adverse events leading to discontinuation or death occurred.Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with biliary tract cancer. Gemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study (NCT03875235) as first-line treatment in patients with advanced biliary tract cancer.AstraZeneca; National Research Foundation of Korea (Grant No. 2021R1A2C2007430).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苏y完成签到,获得积分10
2秒前
华仔应助嘻哈采纳,获得10
2秒前
科研通AI5应助优秀的绿蕊采纳,获得10
5秒前
健忘的初翠完成签到,获得积分10
5秒前
7秒前
lwm不想看文献完成签到 ,获得积分10
7秒前
9秒前
拼搏一曲发布了新的文献求助10
10秒前
CAOHOU应助科研通管家采纳,获得10
11秒前
共享精神应助科研通管家采纳,获得10
11秒前
CAOHOU应助科研通管家采纳,获得10
11秒前
SYLH应助科研通管家采纳,获得20
11秒前
乐乐应助科研通管家采纳,获得10
11秒前
汉堡包应助科研通管家采纳,获得10
11秒前
FashionBoy应助科研通管家采纳,获得10
11秒前
桐桐应助科研通管家采纳,获得10
11秒前
11秒前
深情安青应助科研通管家采纳,获得10
11秒前
CAOHOU应助科研通管家采纳,获得10
11秒前
SYLH应助科研通管家采纳,获得10
11秒前
CAOHOU应助科研通管家采纳,获得10
11秒前
Owen应助科研通管家采纳,获得10
12秒前
SYLH应助科研通管家采纳,获得10
12秒前
SYLH应助科研通管家采纳,获得10
12秒前
12秒前
酷波er应助科研通管家采纳,获得10
12秒前
wushuwen发布了新的文献求助10
12秒前
13秒前
xuan完成签到,获得积分10
14秒前
完美世界应助段一帆采纳,获得10
16秒前
少敏敏完成签到,获得积分10
18秒前
may发布了新的文献求助10
18秒前
23秒前
25秒前
兜兜关注了科研通微信公众号
25秒前
wbh完成签到,获得积分10
26秒前
太牛的GGB发布了新的文献求助10
26秒前
wbh发布了新的文献求助10
28秒前
乐乐应助may采纳,获得10
28秒前
顺利的梦菲完成签到 ,获得积分10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173